NCT05456243View on ClinicalTrials.gov

Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Kidney Transplant
Interventions
BIOLOGICAL

Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)

Single intra-arterial infusion of 1 x 10\^5 cells/kg

BIOLOGICAL

High dose adipose tissue derived mesenchymal stromal cells (A-MSC)

Single intra-arterial infusion of 5 x 10\^5 cells/kg infused over 5 minutes

Trial Locations (1)

55905

RECRUITING

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05456243 - Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter